

Figures 1A - 1B

FPF=95% MMAD=2.8μm




Figure 2




Figure 3







Figure 4








Figures 5A - 5B




Figures 6A - 6B









Figures 7A - 7D




Figure 8







Figure 9








Figures 10A - 10B



B. IL-2 (spleen)







Figures 11A - 11C






Figure 12

# A. Activation of TcH by HA 110-120 integrated in Ig, in context of B lymphoma APC




B. In vitro stimulation of TcH by IgHA in context of B lymphoma APC (18 hours incubation)





Figures 13A - 13B

# A. InsB / a-CD3 stimulated splenocytes





# B. GAD/ anti-CD3 stimulated splenocytes







Figures 14A - 14C








Figures 15A - 15C





Figures 16A - 16B






Figure 17

### A. Th profile in MALT 500 □ IFN-gamma 400 **■** IL-4 300 200 100 0 Sal-HES-Man-Live WSN WSN WSN WSN




Figures 18A - 18B



**Figures 19A - 19C** 


### 

## B. Kinetics of disease (8-20w)





Figures 20A - 20B

# A. IL-4 producing cells (spleen 11-12 w) 100000 10000 1000 1000 Naïve SDLM-Man-InsB (8-10w)




Figures 21A - 21B






Figures 22A - 22B

### A. Number cells/LN (12-13 weeks)



### B. Number cells/LN (30-31 weeks)



Figures 23A - 23B




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31